BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22795293)

  • 41. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
    J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy.
    Attia FM; Hassan AM; El-Maraghy NN; Ibrahium GH
    Cancer Biomark; 2011-2012; 11(1):41-7. PubMed ID: 22820139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.
    Shah MS; Fogelman DR; Raghav KP; Heymach JV; Tran HT; Jiang ZQ; Kopetz S; Daniel CR
    Cancer; 2015 Sep; 121(17):2968-75. PubMed ID: 25975416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of some inflammatory markers in patients with lymphoma.
    Hamed Anber N; El-Sebaie AH; Darwish NHE; Mousa SA; Shamaa SS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30814315
    [No Abstract]   [Full Text] [Related]  

  • 45. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort.
    Conroy SM; Maskarinec G; Morimoto Y; Franke AA; Cooney RV; Wilkens LR; Goodman MT; Hernadez BY; Le Marchand L; Henderson BE; Kolonel LN
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):337-47. PubMed ID: 23300021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteinuria is a simple sign of systemic inflammation that leads to a poor prognosis in individuals affected with non-Hodgkin lymphoma.
    Hara M; Ando M; Maeda Y; Tsuchiya K; Nitta K
    Clin Nephrol; 2014 Jul; 82(1):51-7. PubMed ID: 24887301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects.
    da Silva PB; Perini GF; Pereira Lde A; Sacconato EM; Penna AM; Garibaldi J; Cavalcante E; Baiocchi OC
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S151-7. PubMed ID: 26297269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.
    Tedeschi R; Bidoli E; Bortolin MT; Schioppa O; Vaccher E; De Paoli P
    Oncotarget; 2015 Oct; 6(30):30334-42. PubMed ID: 26296972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
    Marri PR; Hodge LS; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Cerhan JR; Novak AJ; Ansell SM
    Clin Cancer Res; 2013 Dec; 19(24):6812-9. PubMed ID: 24141626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.
    Purdue MP; Lan Q; Bagni R; Hocking WG; Baris D; Reding DJ; Rothman N
    Cancer Res; 2011 Jul; 71(14):4898-907. PubMed ID: 21632552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.
    Vendrame E; Hussain SK; Breen EC; Magpantay LI; Widney DP; Jacobson LP; Variakojis D; Knowlton ER; Bream JH; Ambinder RF; Detels R; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):343-9. PubMed ID: 24220912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
    Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients.
    Chen ZY; He WZ; Peng LX; Jia WH; Guo RP; Xia LP; Qian CN
    Int J Cancer; 2015 Feb; 136(3):584-92. PubMed ID: 24916890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.
    Fayad L; Cabanillas F; Talpaz M; McLaughlin P; Kurzrock R
    Leuk Lymphoma; 1998 Aug; 30(5-6):563-71. PubMed ID: 9711918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis.
    Fahmi MN; Pradjatmo H; Astuti I; Nindrea RD
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):315-323. PubMed ID: 33639643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased Cytokine Levels Assist in the Diagnosis of Respiratory Bacterial Infections or Concurrent Bacteremia in Patients With Non-Hodgkin's Lymphoma.
    Zhang L; Zhang J; He H; Ling X; Li F; Yang Z; Zhao J; Li H; Yang T; Zhao S; Shi K; Guan X; Zhao R; Li Z
    Front Cell Infect Microbiol; 2022; 12():860526. PubMed ID: 35463642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
    Etto L; Lacerda E; Baiocchi O; Silva V; Dalboni M; Alves A; Silva M; Vettore A; Colleoni G
    Leuk Lymphoma; 2008 Feb; 49(2):257-64. PubMed ID: 18231911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study.
    Kathpalia M; Mishra P; Majid A; Khan MA; Sharma A; Bhurani D; Nidhi
    J Neuroimmunol; 2024 Jul; 392():578372. PubMed ID: 38788317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
    Khalifa KA; Alkilani AA; Ismail H; Soliman MA
    J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.
    Aschebrook-Kilfoy B; Zheng T; Foss F; Ma S; Han X; Lan Q; Holford T; Chen Y; Leaderer B; Rothman N; Zhang Y
    J Cancer Surviv; 2012 Mar; 6(1):102-14. PubMed ID: 22113576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.